
pmid: 15110144
Early recognition of potential QT/TdP liability is now an essential component of the drug discovery/drug development program. The hERG assay is an indispensable step and a high-quality assay must accompany any investigational new drug (IND) application. While it is the gold standard at present, the hERG assay is too labor-intensive and too low throughput to be used as a screen early in the discovery/development process. A variety of indirect high throughput screens have been used.
ERG1 Potassium Channel, Long QT Syndrome, Death, Sudden, Cardiac, Potassium Channels, Potassium Channels, Voltage-Gated, Drug Evaluation, Preclinical, Humans, Terfenadine, Ether-A-Go-Go Potassium Channels
ERG1 Potassium Channel, Long QT Syndrome, Death, Sudden, Cardiac, Potassium Channels, Potassium Channels, Voltage-Gated, Drug Evaluation, Preclinical, Humans, Terfenadine, Ether-A-Go-Go Potassium Channels
| selected citations These citations are derived from selected sources. This is an alternative to the "Influence" indicator, which also reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically). | 121 | |
| popularity This indicator reflects the "current" impact/attention (the "hype") of an article in the research community at large, based on the underlying citation network. | Top 10% | |
| influence This indicator reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically). | Top 10% | |
| impulse This indicator reflects the initial momentum of an article directly after its publication, based on the underlying citation network. | Top 10% |
